ArticleRadiation oncology journal2025
Can lymphocytic toxicity be induced by radiation dose to the bowel bag in whole pelvic radiotherapy?
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.Cancer immunology, immunotherapy : CII · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeLymphocytopenia is a known side effect of radiation exposure to the bone marrow. However, the hematological impact of irradiating the bowel bag-a highly vascularized region containing numerous mesenteric lymph nodes-remains poorly understood. This study aimed to examine whether radiation to the bowel bag leads to a decrease in absolute lymphocyte count (ALC) during pelvic radiotherapy. MATERIALS AND
methodsWe retrospectively analyzed 168 patients with prostate, bladder, gynecologic, and gastrointestinal cancers who received whole pelvic radiotherapy (45-60 Gy) without concurrent chemotherapy between October 2016 and November 2022. Dose-volume parameters (V5, V10, V15, V20, and V30) representing the percentage of bowel bag volume receiving ≥x Gy were calculated. The primary endpoint was grade 3 lymphocytopenia (ALC 200-500/μL) measured at 3 weeks post-treatment initiation. Logistic regression analysis evaluated associations between bowel bag dosimetric parameters and severe lymphocytopenia.
resultsThe overall lymphocytopenia rate was 92.3%, with 23.8% developing grade 3 toxicity. Logistic regression analysis demonstrated that higher radiation doses to the bowel bag at V5, V10, and V15 significantly increased the risk of grade 3 lymphocytopenia (odds ratios, 3.0 to 5.9, all p < 0.01).
conclusionRadiation dose to the bowel bag independently predicts severe lymphocytopenia during pelvic radiotherapy. These findings suggest that dose constraints to the bowel bag should be considered alongside bone marrow sparing techniques to preserve hematopoietic function. Prospective validation and development of bowel bag dose-volume guidelines are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.